GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jubilant Pharmova Ltd (NSE:JUBLPHARMA) » Definitions » Cyclically Adjusted PS Ratio

Jubilant Pharmova (NSE:JUBLPHARMA) Cyclically Adjusted PS Ratio : 2.11 (As of Jun. 06, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Jubilant Pharmova Cyclically Adjusted PS Ratio?

As of today (2025-06-06), Jubilant Pharmova's current share price is ₹1142.30. Jubilant Pharmova's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹541.84. Jubilant Pharmova's Cyclically Adjusted PS Ratio for today is 2.11.

The historical rank and industry rank for Jubilant Pharmova's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:JUBLPHARMA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.38   Med: 1.04   Max: 2.31
Current: 2.17

During the past years, Jubilant Pharmova's highest Cyclically Adjusted PS Ratio was 2.31. The lowest was 0.38. And the median was 1.04.

NSE:JUBLPHARMA's Cyclically Adjusted PS Ratio is ranked worse than
50.27% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.14 vs NSE:JUBLPHARMA: 2.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jubilant Pharmova's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹120.698. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹541.84 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jubilant Pharmova Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Jubilant Pharmova's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jubilant Pharmova Cyclically Adjusted PS Ratio Chart

Jubilant Pharmova Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 0.74 0.52 1.06 1.65

Jubilant Pharmova Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.06 1.36 2.10 2.02 1.65

Competitive Comparison of Jubilant Pharmova's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jubilant Pharmova's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jubilant Pharmova's Cyclically Adjusted PS Ratio falls into.


;
;

Jubilant Pharmova Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Jubilant Pharmova's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1142.30/541.84
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jubilant Pharmova's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Jubilant Pharmova's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=120.698/157.5517*157.5517
=120.698

Current CPI (Mar. 2025) = 157.5517.

Jubilant Pharmova Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 89.467 99.841 141.182
201509 93.049 101.753 144.074
201512 84.940 102.901 130.052
201603 98.441 102.518 151.286
201606 83.395 105.961 123.999
201609 89.658 105.961 133.311
201612 94.572 105.196 141.640
201703 100.437 105.196 150.424
201706 103.925 107.109 152.869
201709 104.025 109.021 150.331
201712 131.014 109.404 188.672
201803 142.728 109.786 204.825
201806 131.367 111.317 185.930
201809 144.077 115.142 197.144
201812 151.015 115.142 206.638
201903 150.776 118.202 200.969
201906 135.116 120.880 176.107
201909 140.440 123.175 179.635
201912 93.869 126.235 117.156
202003 94.008 124.705 118.769
202006 70.297 127.000 87.208
202009 97.264 130.118 117.771
202012 109.480 130.889 131.781
202103 97.443 131.771 116.508
202106 101.393 134.084 119.139
202109 102.591 135.847 118.982
202112 81.434 138.161 92.863
202203 95.199 138.822 108.043
202206 90.528 142.347 100.197
202209 99.777 144.661 108.668
202212 96.316 145.763 104.106
202303 104.174 146.865 111.755
202306 97.906 150.280 102.643
202309 105.069 151.492 109.272
202312 104.698 152.924 107.866
202403 110.623 153.035 113.888
202406 108.305 155.789 109.531
202409 109.481 157.882 109.252
202412 114.322 158.323 113.765
202503 120.698 157.552 120.698

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jubilant Pharmova  (NSE:JUBLPHARMA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Jubilant Pharmova Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Jubilant Pharmova's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jubilant Pharmova Business Description

Traded in Other Exchanges
Address
1A, Sector 16A, Noida, UP, IND, 201301
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.

Jubilant Pharmova Headlines

No Headlines